Nanjing Vazyme Biotech Co (SHSE:688105) Beginning Cash Position: ¥249 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688105 Nanjing Vazyme Biotech Co Ltd SHSE:688105
69 GF Score
Price ¥19.50
GF Value ¥21.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Nanjing Vazyme Biotech Co Beginning Cash Position?

Nanjing Vazyme Biotech Co SHSE:688105 -0.61% 69 Beginning Cash Position is ¥249 Mil as of Jun. 2026. GuruFocus rates SHSE:688105 with a GF Score™ of 69/100 and a GF Value™ of ¥21.57 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Nanjing Vazyme Biotech Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was ¥249 Mil.

Nanjing Vazyme Biotech Co's quarterly Beginning Cash Position increased from Dec. 2025 (¥182 Mil) to Mar. 2026 (¥197 Mil) and increased from Mar. 2026 (¥197 Mil) to Jun. 2026 (¥249 Mil).

Nanjing Vazyme Biotech Co's annual Beginning Cash Position declined from Dec. 2023 (¥1,345 Mil) to Dec. 2024 (¥848 Mil) and declined from Dec. 2024 (¥848 Mil) to Dec. 2025 (¥423 Mil).

Nanjing Vazyme Biotech Co Beginning Cash Position Related Terms

Nanjing Vazyme Biotech Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Nanjing Vazyme Biotech Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Vazyme Biotech Co Beginning Cash Position Chart

Nanjing Vazyme Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only 221.60 1,477.77 1,344.59 848.19 423.21

Nanjing Vazyme Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 295.91 204.69 182.04 197.23 249.33
SHSE:688105
69GF Score
Nanjing Vazyme Biotech Co Ltd SHSE:688105
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Vazyme Biotech Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of ¥249 Mil mean?
Nanjing Vazyme Biotech Co (SHSE:688105) has a Beginning Cash Position of ¥249 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nanjing Vazyme Biotech Co and its competitors.
Is Nanjing Vazyme Biotech Co's Beginning Cash Position too high?
Nanjing Vazyme Biotech Co's current Beginning Cash Position is ¥249 Mil. Overall, Nanjing Vazyme Biotech Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vazyme Biotech Co's Beginning Cash Position compare to VRTX and REGN?
Nanjing Vazyme Biotech Co's Beginning Cash Position of ¥249 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Nanjing Vazyme Biotech Co and its competitors. Nanjing Vazyme Biotech Co's current Beginning Cash Position is ¥249 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vazyme Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co (SHSE:688105) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.57, compared to a current price of ¥19.50 — trading 9.6% below its estimated fair value. The current Beginning Cash Position is ¥249 Mil. Nanjing Vazyme Biotech Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Nanjing Vazyme Biotech Co (SHSE:688105), the current Beginning Cash Position is ¥249 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanjing Vazyme Biotech Co (SHSE:688105) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co stock appears to be undervalued. The current stock price of ¥19.50 is trading 9.6% below its estimated GF Value™ of ¥21.57. GuruFocus considers Nanjing Vazyme Biotech Co to be Modestly Undervalued.

Key valuation signals for SHSE:688105:

  • Beginning Cash Position: ¥249 Mil
  • GF Value™: ¥21.57 vs. price of ¥19.50 (9.6% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanjing Vazyme Biotech Co Business Description

Address Kechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
69GF Score

Get the complete analysis for SHSE:688105

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.50
Price
¥21.57
GF Value